Royal Bank of Canada set a $48.00 price objective on Mylan and gave the company a "hold" rating in a report on Thursday, March 2nd. AlphaOne also assigned news stories about the company an impact score of 93 out of 100, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near term. Finally, Wells Fargo & Co restated a "market perform" rating and set a $40.00 target price on shares of Mylan in a report on Friday, April 14th. Barclays PLC restated an "equal weight" rating and issued a $47.00 target price (up from $44.00) on shares of Mylan in a report on Saturday, March 11th. Guggenheim reissued a neutral rating on shares of Mylan in a research report on Friday, March 3rd. Leerink Swann maintained Mylan N.V. (NASDAQ:MYL) on Monday, August 15 with "Outperform" rating. The stock has a consensus rating of "Buy" and a consensus target price of $51.58.
Mylan (NASDAQ:MYL) traded down 1.29% on Thursday, hitting $38.15. Advisors Asset Management Inc. now owns 69,205 shares of the company's stock valued at $2,698,000 after buying an additional 5,391 shares during the period. Mylan has a 12 month low of $33.60 and a 12 month high of $50.40. The firm's 50-day moving average is $38.13 and its 200 day moving average is $38.73.
The price/earnings ratio (P/E) is 38.50 and the forward P/E ratio stands at 6.80. Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ, TASE: MYL) ("Mylan") recently declared that data from several studies of revefenacin (TD-4208) will be presented at the American Thoracic Society (ATS) International Conference, which is being held in Washington, D.C., May 19-24, 2017. The company reported $0.93 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.92 by $0.01. The firm had revenue of $2.72 billion for the quarter, compared to the consensus estimate of $2.81 billion. Mylan had a return on equity of 22.04% and a net margin of 2.50%. State Board of Administration of Florida Retirement System now owns 638,131 shares of the company's stock worth $24,881,000 after buying an additional 1,949 shares in the last quarter. The share price of MYL has increased by over 0.55% in the last six months.
A look at some of the inputs to technical analysis model shows how Mylan N.V. current price compares to its recent moving averages.
ILLEGAL ACTIVITY NOTICE: "Mylan (MYL) Price Target Cut to $36.00" was originally published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another site, it was illegally copied and reposted in violation of U.S. & worldwide trademark & copyright law. The correct version of this piece of content can be accessed at https://www.themarketsdaily.com/2017/05/18/oakworth-capital-inc-boosts-position-in-mylan-myl-updated-updated.html.
In related news, major shareholder Laboratories Abbott sold 44,000,000 shares of the business's stock in a transaction dated Thursday, March 23rd. Princeton Portfolio Strategies Group Llc sold 71,750 shares as Mylan Labs (MYL)'s stock 0.00%. It is positive, as 3 investors sold MYL shares while 2 reduced holdings. Wellington Shields Capital Management LLC bought a new stake in Mylan during the third quarter worth $936,000. Finally, Endurant Capital Management LP raised its stake in Mylan by 37.6% in the first quarter. Mosaic Family Wealth LLC now owns 3,600 shares of the company's stock valued at $137,000 after buying an additional 400 shares during the last quarter. Bank of Nova Scotia raised its stake in Mylan by 1.9% in the first quarter. WealthTrust Axiom LLC now owns 18,310 shares of the company's stock worth $697,000 after buying an additional 810 shares during the period.